Biotechnology was born in the San Francisco Bay Area in the 1970s, and by most ways of keeping score, it remains the world’s No. 1 life sciences industry cluster. But what will the Bay Area biotech landscape look like 20 years from now? Will this place maintain its standing as the world leader in university and corporate research, venture financing, and entrepreneurial activity? Will the Bay Area continue to lead in development of new drugs, medical devices, and diagnostics? Or will San Francisco lose some of its edge as more innovators gravitate to secondary hubs in the U.S. with high quality of life and lower cost of living, or emerging international clusters in Singapore, China, and India? Xconomy and QB3 will bring together a select group of innovators and visionaries in the heart of San Francisco’s Mission Bay district for an intimate, interactive discussion of these and other key questions about the future of San Francisco-area life sciences.
Jeff Bluestone, Executive Vice Chancellor and Provost, UCSF, Director, UCSF Diabetes Center
Reg Kelly, Director, QB3
Randy Scott, Founder and Executive Chairman, Genomic Health
Peter Hirth, Co-founder and CEO, Plexxikon
Corey Goodman, Co-founder and Managing Director, venBio
Dave Martin, CEO, AvidBiotics
Bill Newell, CEO, Sutro Biopharma
Nancy Stagliano, CEO, CytomX Therapeutics
Registration & Networking: 5:00 – 6:00 pm
Program: 6:00 – 7:30 pm
Networking reception: 7:30 – 8:30 pm
Early Bird Rate (ends Feb. 15) $75
Regular Registration: $95
Walk-in Registration: $125
Student Registration: $20
Tickets are transferable but not refundable.
To inquire about press registration, email email@example.com.